H-Gemcitabine: A new gemcitabine prodrug for treating cancer

Madhuri Dasari; Abhinav P. Acharya; Dongin Kim; Seungjun Lee; Sungmun Lee; Jeanne Rhea; Ross Molinaro; Niren Murthy

doi:10.1021/bc300095m

H-Gemcitabine: A new gemcitabine prodrug for treating cancer

Madhuri Dasari
, Abhinav P. Acharya
, Dongin Kim
, Seungjun Lee
, Sungmun Lee
, Jeanne Rhea
, Ross Molinaro
, Niren Murthy

Biomedical Engineering & Biotechnology

Georgia Institute of Technology
Emory University School of Medicine
University of California, Berkeley

Research output: Contribution to journal › Article › peer-review

43 Scopus citations

Abstract

In this report, we present a new strategy for targeting chemotherapeutics to tumors, based on targeting extracellular DNA. A gemcitabine prodrug was synthesized, termed H-gemcitabine, which is composed of Hoechst conjugated to gemcitabine. H-gemcitabine has low toxicity because it is membrane-impermeable; however, it still has high tumor efficacy because of its ability to target gemcitabine to E-DNA in tumors. We demonstrate here that H-gemcitabine has a wider therapeutic window than free gemcitabine.

Original language	British English
Pages (from-to)	4-8
Number of pages	5
Journal	Bioconjugate Chemistry
Volume	24
Issue number	1
DOIs	https://doi.org/10.1021/bc300095m
State	Published - 16 Jan 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1021/bc300095m

OpenUrl availability

Full text

Cite this

@article{3ed538667eaf409a92567e3867ac080e,

title = "H-Gemcitabine: A new gemcitabine prodrug for treating cancer",

abstract = "In this report, we present a new strategy for targeting chemotherapeutics to tumors, based on targeting extracellular DNA. A gemcitabine prodrug was synthesized, termed H-gemcitabine, which is composed of Hoechst conjugated to gemcitabine. H-gemcitabine has low toxicity because it is membrane-impermeable; however, it still has high tumor efficacy because of its ability to target gemcitabine to E-DNA in tumors. We demonstrate here that H-gemcitabine has a wider therapeutic window than free gemcitabine.",

author = "Madhuri Dasari and Acharya, \{Abhinav P.\} and Dongin Kim and Seungjun Lee and Sungmun Lee and Jeanne Rhea and Ross Molinaro and Niren Murthy",

year = "2013",

month = jan,

day = "16",

doi = "10.1021/bc300095m",

language = "British English",

volume = "24",

pages = "4--8",

journal = "Bioconjugate Chemistry",

issn = "1043-1802",

publisher = "American Chemical Society",

number = "1",

}

TY - JOUR

T1 - H-Gemcitabine

T2 - A new gemcitabine prodrug for treating cancer

AU - Dasari, Madhuri

AU - Acharya, Abhinav P.

AU - Kim, Dongin

AU - Lee, Seungjun

AU - Lee, Sungmun

AU - Rhea, Jeanne

AU - Molinaro, Ross

AU - Murthy, Niren

PY - 2013/1/16

Y1 - 2013/1/16

N2 - In this report, we present a new strategy for targeting chemotherapeutics to tumors, based on targeting extracellular DNA. A gemcitabine prodrug was synthesized, termed H-gemcitabine, which is composed of Hoechst conjugated to gemcitabine. H-gemcitabine has low toxicity because it is membrane-impermeable; however, it still has high tumor efficacy because of its ability to target gemcitabine to E-DNA in tumors. We demonstrate here that H-gemcitabine has a wider therapeutic window than free gemcitabine.

AB - In this report, we present a new strategy for targeting chemotherapeutics to tumors, based on targeting extracellular DNA. A gemcitabine prodrug was synthesized, termed H-gemcitabine, which is composed of Hoechst conjugated to gemcitabine. H-gemcitabine has low toxicity because it is membrane-impermeable; however, it still has high tumor efficacy because of its ability to target gemcitabine to E-DNA in tumors. We demonstrate here that H-gemcitabine has a wider therapeutic window than free gemcitabine.

UR - https://www.scopus.com/pages/publications/84872540658

U2 - 10.1021/bc300095m

DO - 10.1021/bc300095m

M3 - Article

C2 - 23237198

AN - SCOPUS:84872540658

SN - 1043-1802

VL - 24

SP - 4

EP - 8

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

IS - 1

ER -

H-Gemcitabine: A new gemcitabine prodrug for treating cancer

Abstract

UN SDGs

Access to Document

OpenUrl availability

Other files and links

Fingerprint

Cite this